Form 6-K Aptose Biosciences Inc., For: Oct 30

�

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

�

Report of Foreign Issuer

�

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

�

For the Month of October, 2014

�

Commission File Number 1-32001

�

Aptose Biosciences Inc.

(formerly Lorus Therapeutics Inc.)

(Translation of registrants name into English)

�

�

2 Meridian Road, Toronto, Ontario M9W 4Z7

---

(Address of principal executive offices)

�

�

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

�

Form 20-F �����Form 40-F 

�

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

�

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

�

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

�

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrants home country), or under the rules of the home country exchange on which the registrants securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrants security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

�

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

�

Yes �����No 

�

If Yes is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):82-_______________.

��

�

�

SIGNATURE

�

Pursuant to the requirements of the Securities Exchange Act of��1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

�

�	Aptose Biosciences Inc.
�	�
�	�
Date:� October 30, 2014	By:	�/s/ Gregory Chow
�	�	Gregory Chow
�	�	Senior Vice President and Chief Financial Officer

�

�

�

EXHIBIT INDEX

�

99.1	Press Release dated October 30, 2014 - Aptose Biosciences To Host Conference Call and Webcast For Four Month Interim Period Ended September 30, 2014

�

�

Exhibit 99.1

�

�

�

Aptose Biosciences To Host Conference Call and Webcast For Four Month Interim Period Ended September 30, 2014

SAN DIEGO and TORONTO, Oct. 30, 2014 /CNW/ - Aptose Biosciences Inc. (Aptose)� (NASDAQ: APTO; TSX: APS), a clinical-stage company developing targeted agents and molecular diagnostics to treat the underlying mechanisms of cancer, today announced it intends to release financial results for the four month interim period ended September 30, 2014, on Tuesday, November 4, 2014 after the close of the market.� The company intends to host a conference call on the same day at 5:00 p.m. ET to discuss the financial results.

Effective July 15, 2014, Aptose changed its fiscal year end from May 31 to December 31.� As a result of that change, the current interim period is for the four months ended September 30, 2014.

Participants can access the conference call by dialing 1-888-231-8191 (North American toll free number) or 647-427-7450 (local).� The conference call will be available via a live webcast at http://www.newswire.ca/en/webcast/detail/1435873/1595769, and will also be available through a link on the Investor Relations section of Aptose's website at http://www.aptose.com/events/.� Please log on to the webcast at least 10 minutes prior to the start of the call to ensure time for any software downloads that may be required.� An archived version of the webcast will be available on the company's website for 30 days.�� An audio replay of the webcast will be available approximately two hours after the conclusion of the call for 30 days by dialing 1-855-859-2056, using the passcode 28685150.

The press release, financial statements and the management's discussion and analysis for the four month interim period ended September 30, 2014 will be available on the Company's website at www.aptose.com.

About Aptose

Aptose Biosciences is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. Aptose is advancing new therapeutics focused on novel cellular targets on the leading edge of cancer research coupled with companion diagnostics to identify the optimal patient population for our products. The company's small molecule cancer therapeutics pipeline includes products designed to provide additive or synergistic efficacy with existing anti-cancer therapies and regimens without overlapping toxicities. Aptose Biosciences Inc. is listed on the TSX under the symbol APS and is on NASDAQ under the symbol APTO.

This press release contains forward-looking statements within the meaning of Canadian and U.S. securities laws. Such statements include, but are not limited to, statements relating to Aptose's plans, objectives, expectations and intentions and other statements including words such as "continue", "expect", "intend", "will", "should", "would", "may", and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements described in this press release. Such expressed or implied factors include, among others: changes in our stock price; our ability to meet listing requirements; our ability to obtain the capital required for research and operations; the inherent risks in early stage drug development including demonstrating efficacy; development time/cost and the regulatory approval process; the progress of our clinical trials; our ability to find and enter into agreements with potential partners; our ability to attract and retain key personnel; changing market conditions; stock market volatility; and other risks detailed from time-to-time in our ongoing quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission.

Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled "Risk Factors" in our filings with Canadian securities regulators and the United States Securities and Exchange Commission underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.

SOURCE Aptose Biosciences Inc.

PDF available at: http://stream1.newswire.ca/media/2014/10/30/20141030_C9237_DOC_EN_43143.pdf

�

%CIK: 0000882361

For further information:

Aptose Biosciences
Greg Chow, CFO
416-798-1200
[email protected]

BCC Partners
Karen L. Bergman or Susan Pietropaolo
650-575-1509 or 845-638-6290
[email protected] or�[email protected]

CO: Aptose Biosciences Inc.

CNW 07:01e 30-OCT-14

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• SKEL fjárfestingafélag hf.: Styrkás finalizes the purchase of Stólpi Gámar ehf. and affiliated companies.
• TEAMSTERS IN THREE STATES FILE UNFAIR LABOR PRACTICE CHARGES AGAINST PEPSI
• Introducing: The Dr. Vidal Sheen Grant for Healthcare Students